Login
Zynerba Pharmaceuticals NASDAQ: ZYNE
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions
| Name | Zynerba Pharmaceuticals |
| Ticker | ZYNE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Price | 3.28 |
| 52W Low/High | 2.90 / 8.57 |
| Market cap | 82 M |
| 1Y Total Return |
-58.64%
Weak |
| 1Y Volatility |
99.64%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions
Details
| Ticker | ZYNE |
| Name | Zynerba Pharmaceuticals |
| ISIN | US98986X1090 |
| CUSIP | 98986X109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 9/25/20
| Close Price | 3.28 |
| 52W Low/High | 2.90 / 8.57 |
| Market cap | 82 M |
| 1Y Total Return |
-58.64%
Weak |
| 1Y Volatility |
99.64%
High Risk |
| Beta | 3.20 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -3.07 |
| Diluted Earnings / Share | -1.86 |
| ROE | - |
| ROIC | - |
| Price / Revenue | - |
| Price / Book | 1.2 |
| Price / CF | -2.1 |
| Current Ratio | 6.5 |
| Cur.Liabilities / Tot.Liabilities | 1.0 |
| Financial Leverage | 0.00 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Gross Profit |
-
|
0
|
-
|
-
|
0
|
-
|
|
| R&D |
30
|
24
|
29
|
21
|
13
|
-
|
|
| EBITDA |
-45
|
-36
|
-41
|
-28
|
-20
|
-
|
|
| Operating Income |
-46
|
-37
|
-41
|
-29
|
-20
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
26
|
22
|
14
|
13
|
9
|
-
|
|
| EPS exc. Extra |
-1.86
|
-1.84
|
-3.04
|
-2.63
|
-2.30
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
87
|
96
|
52
|
79
|
36
|
9
|
|
| Cash, Eq & Invt ShortTerm |
77
|
89
|
43
|
70
|
32
|
6
|
|
| Total Current Assets |
85
|
94
|
49
|
76
|
36
|
9
|
|
| Total Non-Current Assets |
2
|
2
|
3
|
3
|
0
|
0
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
13
|
10
|
12
|
8
|
5
|
21
|
|
| Total Current Liabilities |
13
|
10
|
11
|
8
|
5
|
4
|
|
| Long Term Debt |
0
|
0
|
1
|
0
|
0
|
17
|
|
| Shareholder equity |
74
|
86
|
40
|
71
|
31
|
-11
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-40
|
-29
|
-30
|
-26
|
-16
|
-
|
|
| Depreciation |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Cash from Investing |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Capex |
0
|
0
|
0
|
0
|
0
|
-
|
|
| Cash from Financing |
29
|
75
|
3
|
65
|
42
|
-
|
|
| Stock Issued |
30
|
77
|
3
|
65
|
42
|
-
|
|
| Debt (LT) Issued |
-1
|
-2
|
0
|
0
|
0
|
-
|
|
| Free Cash Flow |
-43
|
-37
|
-37
|
-26
|
-19
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
6.5
|
9.4
|
4.3
|
9.7
|
7.1
|
2.3
|
|
| Financial Leverage D/E |
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
-
|
|
| Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available